Article

The clinical use of biotherapies in Parkinson disease already has 30years
history. The transplantation of dopamine fetal cells in the striatum of advanced
patients has proved to be relevant in some patients but randomized efficacy
trials in the US have provided disappointing results. However, cell therapies
might come back on stage with the use of stem cells in the future. Gene therapy
is a more recent strategy relying on viral vectors able to transduce genes coding
either for the enzymes that can increase neurotransmitters production or genes
for trophic factors. Several approaches have been developed in PD and have been
experimented in patients. Although, some of the studies have evidenced
insufficient clinical benefit, other programs, such as those using dopamine
replacement techniques are promising. We find fresh hope in this field that might
be the future of PD treatment. It remains however that advanced PD might not be
the ideal condition to properly benefit from biotherapies and there is a need of
studies at earlier stages of the disease, a time where major change in the
disease course might be expected.
CI - Copyright (c) 2014 Elsevier Masson SAS. All rights reserved.
Traitement - Thérapie génique

Langue : ANGLAIS